Active Surveillance of JAK2V617F Clonal Hematopoiesis Toward Myeloproliferative Neoplasms.
Catching early warning signs of blood-cell mutations before they develop into cancer allows treatment while disease is still minimal.
The study assessed whether active surveillance of JAK2V617F clonal hematopoiesis detects myeloproliferative neoplasms earlier. Surveillance-detected disease had lower variant allele frequency and less marrow fibrosis than referral-detected disease after a median 7.4 years to diagnosis.
What the study was
- Study design
- Prospective longitudinal surveillance cohort with retrospective baseline testing
- Population
- JAK2V617F-positive adults without myeloproliferative neoplasm at baseline
- Sample size
- 92
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Blood advances
Why it surfaced
Longitudinal population data support earlier hematologic disease detection, although the JAK2-positive surveillance cohort was modest
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.